Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Conditions
- Recurrent Fallopian Tube Cancer
- Recurrent Ovarian Epithelial Cancer
- Recurrent Primary Peritoneal Cavity Cancer
Interventions
- DRUG: decitabine
- BIOLOGICAL: NY-ESO-1 peptide vaccine
- DRUG: pegylated liposomal doxorubicin hydrochloride
- BIOLOGICAL: sargramostim
- BIOLOGICAL: incomplete Freund's adjuvant
- OTHER: immunohistochemistry staining method
- OTHER: liquid chromatography
- OTHER: mass spectrometry
- GENETIC: reverse transcriptase-polymerase chain reaction
- OTHER: laboratory biomarker analysis
- GENETIC: DNA methylation analysis
- OTHER: enzyme-linked immunosorbent assay
Sponsor
Roswell Park Cancer Institute
Collaborators